TABLE 2.

Univariate and multivariable analyses for variables associated with OS in non-obesity (n = 505).

Characteristics	Category	Univariate analysis HR (95%CI)	p	Multivariate analysis HR (95%CI)	p
Treatment	Anlotinib vs. placebo	0.704 (0.577–0.858)	0.001	0.706 (0.568–0.877)	0.002
Age	>60 vs. ≤60	1.103 (0.907–1.341)	0.326	1.132 (0.911–1.406)	0.264
Gender	Male vs. female	1.461 (1.194–1.789)	<0.001	1.213 (0.906–1.624)	0.195
Smoking history	Current/former vs. never	1.420 (1.169–1.724)	<0.001	1.208 (0.920–1.586)	0.174
Stage	Ⅳ vs. Ⅲ	1.286 (0.836–1.977)	0.252	1.125 (0.683–1.852)	0.644
ECOG	1–2 vs. 0	1.509 (1.138–2.002)	0.004	1.542 (1.143–2.081)	0.005
Histology	Squamous vs. adenocarcinoma	1.106 (0.862–1.418)	0.429	0.947 (0.714–1.256)	0.704
EGFR mutation	Positive vs. negative	0.717 (0.574–0.896)	0.003	0.717 (0.540–0.952)	0.022
Number of metastases	>3 vs. ≤3	1.573 (1.297–1.908)	<0.001	1.596 (1.291–1.974)	<0.001
Lines of previous chemotherapy	≥3 vs. 1–2	0.810 (0.667–0.985)	0.034	0.760 (0.612–0.944)	0.013
Previous Targeted treatment	Yes vs. no	0.828 (0.682–1.005)	0.056	1.019 (0.787–1.319)	0.886
Radiotherapy history	Yes vs. no	1.153 (0.949–1.401)	0.153	1.151 (0.929–1.427)	0.199

The bold values mean that the p value was considered statistically significant.

Abbreviations: Eastern Cooperative Oncology Group (ECOG); epidermal growth factor receptor (EGFR).